GAA and cancer: Acknowledging the poor bioavailability (<1%) of orally-administered RSV [86, 87], the capacity of RSV-like strategies to target N-glycan branching of PD-L1 and, consequently, decrease the T-cell cytotoxicity threshold via targeting of glycoprotein-processing enzymes such as GAA and α-Man I might be a potential treatment option for cancer patients exhibiting a high neo-antigen, immunologically-active phenotype capable of attracting immune cells that ultimately triggers an unsuccessful tumor-immune cell interaction via PD-L1/PD-1 engagement [24–29, 88–90].